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Abstract
To increase the viability of neural cells in neurodegenerative diseases, after neurotraumas and
ischemic strokes the most important neurotrophic and neuroprotective factors, which can be
used as therapeutic agents were identified in long-term studies in vitro and in vivo. These
include  brain-derived  neurotrophic  factor  (BDNF),  glial-derived  neurotrophic  factor  (GDNF),
insulin-like  growth  factor  (IGF)  and vascular  endothelial  growth  factor  (VEGF).  One of  the
promising  ways  of  the  delivery  of  supporting  neuron  survival  factors  is  considered  to  be
transplantation of  genetically modified cells  overexpressing recombinant therapeutic genes.
This article describes generation of  cellular  delivery vectors of  therapeutic genes -  human
umbilical  cord  blood  mononuclear  cells  genetically  modified  by  dual  cassette  plasmids,
expressing two therapeutic genes. Efficiency of transgene expression was confirmed in vitro
using RT-PCR. Analysis of survival, migration, and phenotype of genetically modified cells was
performed 2 weeks after transplantation into transgenic mice with amyotrophic lateral sclerosis
phenotype.
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